Bibliography
Found 116 results
Filters: Author is Gelman, Benjamin B [Clear All Filters]
Heme oxygenase-1 deficiency accompanies neuropathogenesis of HIV-associated neurocognitive disorders. J Clin Invest. 2014 ;124(10):4459-72.
. HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter. J Neurovirol. 2014 ;20(3):209-18.
Potential roles of microglial cell progranulin in HIV-associated CNS pathologies and neurocognitive impairment. J Neuroimmune Pharmacol. 2014 ;9(2):117-32.
. Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol. 2013 ;19(2):150-6.
Apolipoprotein-E genotype and human immunodeficiency virus-associated neurocognitive disorder: the modulating effects of older age and disease severity. Neurobehavioral HIV Medicine [Internet]. 2013 ;Volume 2013:5:11-22. Available from: http://www.dovepress.com/apolipoprotein-e-genotype-and-human-immunodeficiency-virus-associated--peer-reviewed-article-NBHIV
Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr. 2013 ;62(1):36-42.
Etravirine in CSF is highly protein bound. J Antimicrob Chemother. 2013 ;68(5):1161-8.
Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol. 2013 ;19(4):393-401.
Neurocognitive impairment in HIV-infected individuals with previous syphilis. Int J STD AIDS. 2013 ;24(5):351-5.
Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. Journal of Acquired Immune Deficiency Syndrome [Internet]. 2013 ;62(5):487-495. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23242157
Potential Roles of Microglial Cell Progranulin in HIV-Associated CNS Pathologies and Neurocognitive Impairment. Journal of Neuroimmune Pharmacology: the official journal of the Society on NeuroImmune Pharmacology [Internet]. 2013 ;9(2):117-32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23959579
. Systems analysis of human brain gene expression: mechanisms for HIV-associated neurocognitive impairment and common pathways with Alzheimer's disease. BMC Medical Genomics [Internet]. 2013 ;6(4). Available from: http://www.ncbi.nlm.nih.gov/pubmed/23406646
. Wnt signaling in the pathogenesis of human HIV-associated pain syndromes. Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology [Internet]. 2013 ;8(4):956-64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23737037
. Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers. AIDS [Internet]. 2012 ;26(18):2327-2335. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23018443
Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol. 2012 ;18(2):81-90.
Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. Virology. 2012 ;433(2):498-505.
Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr. 2012 ;59(4):376-81.
Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. AIDS. 2012 ;26(7):890-3.
Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol. 2012 ;18(6):511-20.
The National NeuroAIDS Tissue Consortium Brain Gene Array: Two Types of HIV-Associated Neurocognitive Impairment. PLoS One [Internet]. 2012 ;7(9). Available from: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0046178
Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis. J Neuroimmune Pharmacol [Internet]. 2012 ;8:1-15. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419353/
. Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother. 2012 ;56(4):1985-9.
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
Deregulation of microRNAs by HIV-1 Vpr protein leads to the development of neurocognitive disorders. J Biol Chem [Internet]. 2011 ;286:34976-85. Available from: http://www.ncbi.nlm.nih.gov/pubmed?term=21816823
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2011 ;66(2):354-7.